PFA
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shree Ganesh Biotech (India) Ltd announced audited results for FY25 (year ended March 31, 2025). Total revenue from operations grew to Rs 2,295.76 lakhs from Rs 2,027.77 lakhs in FY24, an increase of about 13%. However, net profit after tax fell sharply to Rs 27.84 lakhs from Rs 62.07 lakhs, a drop of roughly 55%, as expenses climbed faster than revenue. The fourth quarter (Q4 FY25) was particularly weak, posting a net loss of Rs 94.60 lakhs versus a profit of Rs 77.17 lakhs in the preceding quarter (Q3 FY25) and Rs 54.35 lakhs in Q4 FY24. Operating cash flow was negative at Rs (1,021.21) lakhs. The statutory auditor issued an unmodified (clean) opinion on the results.
Mixed picture for shareholders — revenue is growing but profitability has compressed sharply and the latest quarter slipped into a loss, with negative operating cash flow signaling stress in core business operations. Near-term sentiment on the stock is likely to be cautious despite the clean audit report.